87 related articles for article (PubMed ID: 24393856)
1. [Treatment outcome of peptide vaccination for advanced colorectal cancer].
Sugiura F; Inoue K; Kogita A; Yoshioka Y; Hida J; Okuno K; Sukegawa Y
Gan To Kagaku Ryoho; 2013 Nov; 40(12):1584-6. PubMed ID: 24393856
[TBL] [Abstract][Full Text] [Related]
2. [Clinical study of Peptide-cocktail vaccination with tegafur-uracil/leucovorin for advanced colorectal cancer].
Sugiura F; Inoue K; Okuno K; Sukegawa Y
Gan To Kagaku Ryoho; 2012 Nov; 39(12):1760-2. PubMed ID: 23267878
[TBL] [Abstract][Full Text] [Related]
3. [Clinical trial of a seven-peptide vaccine and tegafur-uracil/leucovorin as combination therapy for advanced colorectal cancer].
Inoue K; Sugiura F; Kogita A; Yoshioka Y; Sukegawa Y; Hida J; Okuno K
Gan To Kagaku Ryoho; 2014 Oct; 41(10):1276-9. PubMed ID: 25335716
[TBL] [Abstract][Full Text] [Related]
4. [Preliminary study of Peptide vaccine with UFT/LV as adjuvant setting for stage III colorectal cancer].
Okuno K; Sugiura F; Hida J; Tokoro T; Ishimaru E; Ueda K
Gan To Kagaku Ryoho; 2011 Nov; 38(12):1906-8. PubMed ID: 22202234
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer.
Matsushita N; Aruga A; Inoue Y; Kotera Y; Takeda K; Yamamoto M
Oncol Rep; 2013 Mar; 29(3):951-9. PubMed ID: 23314271
[TBL] [Abstract][Full Text] [Related]
6. IgG response to MHC class I epitope peptides is a quantitative predictive biomarker in the early course of treatment of colorectal cancer using therapeutic peptides.
Kanekiyo S; Hazama S; Takenouchi H; Nakajima M; Shindo Y; Matsui H; Tokumitsu Y; Tomochika S; Tsunedomi R; Tokuhisa Y; Iida M; Sakamoto K; Suzuki N; Takeda S; Yamamoto S; Yoshino S; Okuno K; Udaka K; Kawakami Y; Matsueda S; Ito K; Nagano H
Oncol Rep; 2018 May; 39(5):2385-2392. PubMed ID: 29498403
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome.
Hazama S; Nakamura Y; Takenouchi H; Suzuki N; Tsunedomi R; Inoue Y; Tokuhisa Y; Iizuka N; Yoshino S; Takeda K; Shinozaki H; Kamiya A; Furukawa H; Oka M
J Transl Med; 2014 Mar; 12():63. PubMed ID: 24612787
[TBL] [Abstract][Full Text] [Related]
8. Clinical trial of a 7-peptide cocktail vaccine with oral chemotherapy for patients with metastatic colorectal cancer.
Okuno K; Sugiura F; Inoue K; Sukegawa Y
Anticancer Res; 2014 Jun; 34(6):3045-52. PubMed ID: 24922671
[TBL] [Abstract][Full Text] [Related]
9. Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer.
Aruga A; Takeshita N; Kotera Y; Okuyama R; Matsushita N; Ohta T; Takeda K; Yamamoto M
Clin Cancer Res; 2013 Apr; 19(8):2224-31. PubMed ID: 23479678
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer.
Masuzawa T; Fujiwara Y; Okada K; Nakamura A; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Osawa R; Takeda K; Yoshida K; Tsunoda T; Nakamura Y; Mori M; Doki Y
Int J Oncol; 2012 Oct; 41(4):1297-304. PubMed ID: 22842485
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic T lymphocyte response to peptide vaccination predicts survival in stage III colorectal cancer.
Kawamura J; Sugiura F; Sukegawa Y; Yoshioka Y; Hida JI; Hazama S; Okuno K
Cancer Sci; 2018 May; 109(5):1545-1551. PubMed ID: 29473265
[TBL] [Abstract][Full Text] [Related]
12. Retrospectively comparative evaluation of the first- and second-line chemotherapy with campto and oxaliplatin combined with oral tegafur/uracil (UFT)/leucovorin (LV) in patients with metastatic colorectal cancer.
Hsiao SC; Lin JF; Chuang MT; Lee YA; Wu DL
Int Surg; 2009; 94(4):298-303. PubMed ID: 20302025
[TBL] [Abstract][Full Text] [Related]
13. Association of right-sided tumors with high thymidine phosphorylase gene expression levels and the response to oral uracil and tegafur/leucovorin chemotherapy among patients with colorectal cancer.
Sadahiro S; Suzuki T; Tanaka A; Okada K; Nagase H; Uchida J
Cancer Chemother Pharmacol; 2012 Aug; 70(2):285-91. PubMed ID: 22752215
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of uracil-tegafur with leucovorin in elderly (> or = 75 years old) patients with colorectal cancer: ECOG 1299.
Hochster HS; Luo W; Popa EC; Lyman BT; Mulcahy M; Beatty PA; Benson AB
J Clin Oncol; 2007 Dec; 25(34):5397-402. PubMed ID: 18048821
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV.
Shirao K; Hoff PM; Ohtsu A; Loehrer PJ; Hyodo I; Wadler S; Wadleigh RG; O'Dwyer PJ; Muro K; Yamada Y; Boku N; Nagashima F; Abbruzzese JL
J Clin Oncol; 2004 Sep; 22(17):3466-74. PubMed ID: 15277535
[TBL] [Abstract][Full Text] [Related]
16. Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients.
Hattori T; Mine T; Komatsu N; Yamada A; Itoh K; Shiozaki H; Okuno K
Cancer Immunol Immunother; 2009 Nov; 58(11):1843-52. PubMed ID: 19396597
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy of uracil/tegafur (UFT) plus oral Leucovorin (LV) therapy for colorectal cancer in elderly patients].
Mizushima T; Mizuno H; Ito T; Hoki M; Souma Y; Iwamoto T; Ozawa H; Kanou T; Nakamori Y; Iwase K
Gan To Kagaku Ryoho; 2006 Jul; 33(7):941-4. PubMed ID: 16835484
[TBL] [Abstract][Full Text] [Related]
18. Reduction in γ-glutamyl hydrolase expression is associated with response to uracil and tegafur/leucovorin chemotherapy in patients with colorectal cancer.
Sadahiro S; Suzuki T; Tanaka A; Okada K; Kamijo A; Nagase H; Uchida J
Anticancer Res; 2013 Aug; 33(8):3431-8. PubMed ID: 23898115
[TBL] [Abstract][Full Text] [Related]
19. Retrospective study of S-1 versus tegafur/uracil and oral leucovorin in patients with metastatic colorectal cancer.
Shibahara K; Yamamoto M; Kakeji Y; Sakata H; Maehara Y
Anticancer Res; 2008; 28(3B):1779-83. PubMed ID: 18630459
[TBL] [Abstract][Full Text] [Related]
20. Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials.
Bin Q; Li J; Liao C; Cao Y; Gao F
Colorectal Dis; 2011 Aug; 13(8):837-45. PubMed ID: 20050863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
